The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Infectious Disease Clinical Trials Market Projected To Reach By 2030?
The infectious disease clinical trials market size has shown robust expansion in recent years. This market is set to increase from $15.1 billion in 2025 to $16.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical growth of this market can be attributed to the growing global burden of infectious diseases, increased financial support for vaccine development, the development of multinational clinical trial networks, the adoption of digital systems for trial management, and an increase in public health research efforts.
The infectious disease clinical trials market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $21.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is fueled by several factors, including greater investments in pandemic preparedness, the increasing adoption of AI-assisted patient recruitment, the broadening of global trial decentralization, a heightened emphasis on accelerated regulatory approvals, and the expanding incorporation of digital biomarkers. Significant developments expected in this period encompass the wider embrace of data-driven trial design, a surge in the application of decentralized clinical trial models, the deepening integration of real-world evidence, the proliferation of adaptive trial methodologies, and an increased commitment to rapid pathogen response.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Infectious Disease Clinical Trials Market Growth?
The expansion of healthcare infrastructure is anticipated to fuel the future growth of the infectious disease clinical trials market. This infrastructure encompasses physical sites, medical apparatus, technological advancements, and a skilled workforce, all vital for providing healthcare services and facilitating effective disease prevention, diagnosis, and treatment. The surge in healthcare infrastructure development is attributed to a heightened demand for sophisticated medical services, the increasing prevalence of novel and intricate diseases, and the necessity for adequately equipped facilities staffed by proficient healthcare personnel to ensure prompt diagnosis, therapy, and preventative measures. It directly bolsters clinical trial capacity through the provision of cutting-edge medical facilities, specialized instruments, and improved research capabilities, which are crucial for executing thorough infectious disease investigations. For instance, in January 2025, the American Hospital Association, a US-based non-profit organization, projected that the total number of hospitals in the United States will reach 6,093 by 2025, indicating a steady increase in healthcare facilities across the nation. Consequently, the expansion of healthcare infrastructure is a significant driver for the growth of the infectious disease clinical trials market.
What Are The Different Segment Types In The Infectious Disease Clinical Trials Market Segment Breakdown?
The infectious disease clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications
3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies
4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies
5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users
Subsegments:
1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies
2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies
3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies
4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies
Which Trends Are Contributing To Changes In The Infectious Disease Clinical Trials Market?
Leading companies within the infectious disease clinical trials market are concentrating on advancing research efforts, such as Phase 3 trials for antibiotic candidates, to pinpoint rare side effects and establish optimal dosages. A Phase 3 trial for antibiotic candidates represents a late-stage investigation, testing the drug across a large patient population to assess its safety, effectiveness, and comparison to existing treatments before potential approval for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, initiated a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic specifically engineered to combat CRAB, a critical global source of severe hospital infections. Zosurabalpin’s unique characteristic lies in its innovative mechanism of action, which prevents the transport of lipopolysaccharide essential for constructing the bacterial outer membrane, with no resistance yet reported. The global trial plans to enroll approximately 400 patients to evaluate its safety and effectiveness in comparison to standard treatments. Preliminary research has indicated potent activity against multidrug-resistant bacteria, excellent tolerability, and encouraging pharmacokinetic properties. This positions Zosurabalpin as a potentially transformative solution in addressing the critical challenge of antibiotic resistance.
Who Are The Well-Known Companies In The Infectious Disease Clinical Trials Market?
Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit
Get The Full Infectious Disease Clinical Trials Market Report:
Which Region Accounts For The Largest Portion Of The Infectious Disease Clinical Trials Market?
North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Infectious Disease Clinical Trials Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company
Clinical Trial Management Systems Market Report 2026
Virtual Clinical Trials Market Report 2026
https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report
Clinical Trial Supplies Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-trial-supplies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model